Covington & Burling (Beijing)

Timothy Stratford

Covington & Burling (Beijing)
Lawyer (Managing Partner)

Tim Stratford is managing partner in Covington & Burling Beijing office and a member of the International Trade, Corporate and Public Policy Practice Groups. He is also presently serving as Chairman Emeritus of the American Chamber of Commerce in China. Mr. Stratford’s practice is focused on advising international clients doing business in China and assisting Chinese companies seeking to expand their businesses globally. As a former Assistant U.S. Trade Representative, Mr. Stratford is the most senior former U.S. trade official working as a member of the U.S. business community in China. Except for the five years he spent in Washington, DC in government service (2005-2010), Mr. Stratford has lived and worked continuously in the greater China region since 1982.

Linked authors

Covington & Burling (Washington)
Covington & Burling (London)
Covington & Burling (Brussels)
Covington & Burling (Washington)
Covington & Burling (Washington)

Articles

178 Bulletin

Robert J. Williams, Weishi Li, Timothy Stratford, James J. O’Connell, Yan Luo The Chinese State Administration for Industry and Commerce releases rules on intellectual property regarding competition law

18

Following several years of drafting and public consultations, on April 13 the State Administration for Industry and Commerce of the People’s Republic of China (“SAIC”) released its Rules on the Prohibition of Abuses of Intellectual Property Rights for the Purposes of Eliminating or Restricting (...)

Daniel L. Spiegel, John D. Graubert, Weishi Li, James J. O’Connell, Timothy Stratford, Yan Luo The Chinese National Development and Reform Commission opens a broad investigation into pharmaceutical pricing

27

Earlier this month, China’s National Development and Reform Commission (“NDRC”) announced that it is conducting a wide-ranging probe into the costs and prices of pharmaceutical products sold by more than 60 multinational and domestic companies. NDRC has broad powers to enforce China’s Price Law, (...)

John D. Graubert, James J. O’Connell, Timothy Stratford, Yan Luo The Chinese Supreme Court issues rules governing private antitrust litigations arising from monopolistic conducts

23

On May 8, China’s Supreme People’s Court (“SPC”) issued its Rules on the Application of Laws for Adjudicating Civil Disputes Arising From Monopolistic Conduct (“the Rules”). According to the SPC, the Rules, which take effect June 1, are intended to ease plaintiffs’ burdens and are thus likely to have (...)

John D. Graubert, Miranda Cole, James J. O’Connell, Timothy Stratford The Chinese Ministry of Commerce issues regulations regarding investigations and sanctioning of companies that fail to notify transactions under competition law

10

On January 5, China’s Ministry of Commerce (“MOFCOM”) issued new regulations regarding investigations and sanctioning of companies that fail to notify transactions under China’s Anti- Monopoly Law (“AML”). Under the regulations, which take effect on February 1, non-compliant companies may be fined up (...)

John D. Graubert, James J. O’Connell, Timothy Stratford The US and the Chinese Competition Authorities cooperate on issuing guidance regarding antitrust merger investigations

16

The US and China have taken a step towards closer coordination of their investigations of mergers and other transactions under their respective antitrust laws. Yesterday, after high-level consultations in Washington, the two countries’ antitrust merger control agencies released Guidance for Case (...)

James C. Snipes, Paul Claydon, Scott Cunningham, John D. Graubert, James J. O’Connell, Timothy Stratford The Chinese National Development & Reform Commission fines two pharmaceutical companies for abusing dominant position (Shandong Weifang Shuntong Pharmaceutical / Weifang Huaxin Medicine Trade)

30

China’s National Development & Reform Commission (“NDRC”) announced this week that it has fined two domestic pharmaceutical companies for monopolizing bulk sales of promethazine hydrochloride in violation of the country’s Anti-Monopoly Law (“AML”). The decision, NDRC’s first AML action in the (...)

Send a message